Literature DB >> 2549767

Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report.

H Naganuma1, R Kimurat, A Sasaki, A Fukamachi, H Nukui, K Tasaka.   

Abstract

We report the case of a 26-year-old man in whom glioblastoma multiforme had recurred six months following a subtotal resection. Despite radiotherapy and a course of interferon beta and ACNU, the tumour increased in size (to 3 cm) and there was neurological deterioration. Treatment was then initiated with LAK cells, together with ACNU and interferon beta. After three courses of LAK cells, tumour size was markedly reduced, and at about six months the tumour had nearly disappeared on computed tomographic (CT) scans. At one year, and after nine courses of LAK cell therapy (total dose of 2.7 x 10(9) cells) infused via an Ommaya reservoir and supplemented by ACNU and interferon beta, the tumour has disappeared and the patient is considered to be in complete remission since 6 months. This marked response is thought to be due chiefly to LAK cell therapy. The relatively low dose administered was well-tolerated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549767     DOI: 10.1007/BF01402326

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  12 in total

1.  Comparison of in vitro glioma cell cytotoxicity of LAK cells from glioma patients and healthy subjects.

Authors:  V Bosnes; H Hirschberg
Journal:  J Neurosurg       Date:  1988-08       Impact factor: 5.115

2.  In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes.

Authors:  S K Jacobs; D J Wilson; P L Kornblith; E A Grimm
Journal:  J Neurosurg       Date:  1986-01       Impact factor: 5.115

3.  In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells.

Authors:  R E George; W G Loudon; R P Moser; J M Bruner; P A Steck; E A Grimm
Journal:  J Neurosurg       Date:  1988-09       Impact factor: 5.115

4.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

5.  Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.

Authors:  S K Jacobs; D J Wilson; P L Kornblith; E A Grimm
Journal:  J Neurosurg       Date:  1986-05       Impact factor: 5.115

6.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

7.  Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.

Authors:  K Shimizu; Y Okamoto; Y Miyao; M Yamada; Y Ushio; T Hayakawa; H Ikeda; H Mogami
Journal:  J Neurosurg       Date:  1987-04       Impact factor: 5.115

8.  Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.

Authors:  S K Jacobs; D J Wilson; G Melin; C W Parham; B Holcomb; P L Kornblith; E A Grimm
Journal:  Neurol Res       Date:  1986-06       Impact factor: 2.448

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

2.  Therapy of glioblastoma multiforme: a cumulative experience of 10 years.

Authors:  A Obwegeser; M Ortler; M Seiwald; H Ulmer; H Kostron
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

3.  In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes.

Authors:  Y Sawamura; A C Diserens; N de Tribolet
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

4.  Nonlinear modelling of cancer: bridging the gap between cells and tumours.

Authors:  J S Lowengrub; H B Frieboes; F Jin; Y-L Chuang; X Li; P Macklin; S M Wise; V Cristini
Journal:  Nonlinearity       Date:  2010

5.  Computer simulation of glioma growth and morphology.

Authors:  Hermann B Frieboes; John S Lowengrub; S Wise; X Zheng; Paul Macklin; Elaine L Bearer; Vittorio Cristini
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

6.  Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity.

Authors:  H Naganuma; E Halapi; G Masucci; M Hansson; P Wersäll; C Hising; S Venkateswaran; H Mellstedt; R Kiessling
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

7.  Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.

Authors:  C A Kruse; D H Mitchell; B K Kleinschmidt-DeMasters; D Bellgrau; J M Eule; J R Parra; Q Kong; K O Lillehei
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

8.  Inhibition of tumor necrosis factor-alpha and -beta secretion by lymphokine activated killer cells by transforming growth factor-beta.

Authors:  H Naganuma; A Sasaki; E Satoh; M Nagasaka; S Nakano; S Isoe; K Tasaka; H Nukui
Journal:  Jpn J Cancer Res       Date:  1994-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.